Form 4: BeOne Medicines Director Exercises Options and Sells Over $10 Million in Shares

A BeOne Medicines Ltd. director and 10% owner, Xiaodong Wang, reported exercising stock options and subsequently selling 41,760 American Depositary Shares (ADSs) for over $10 million, while also receiving new restricted share units and stock options.

Summary

• Xiaodong Wang, a Director, 10% Owner, and Chair of the Scientific Advisory Board of BeOne Medicines Ltd. (ONC), filed a Form 4 detailing recent transactions.
• On June 10, 2025, Mr. Wang acquired 98,696 Ordinary Shares as Restricted Share Units (RSUs) at a price of $0, which will vest 1/4th annually starting June 10, 2025.
• On the same date, Mr. Wang exercised options to acquire 542,880 Ordinary Shares (equivalent to 41,760 American Depositary Shares, as each ADS represents 13 Ordinary Shares) at an exercise price of $0.5 per Ordinary Share.
• Immediately following the option exercise, Mr. Wang sold all 41,760 American Depositary Shares (ADSs) in multiple transactions at weighted average prices ranging from $261.2041 to $264.85 per ADS, totaling approximately $10,979,000.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
• Mr. Wang also received a new grant of 185,796 Share Options (Right to Buy) Ordinary Shares with an exercise price of $20.26, vesting over four years starting June 10, 2025, and expiring on June 9, 2035.
• Following these transactions, Mr. Wang directly beneficially owns 5,180,861 Ordinary Shares and 185,796 Share Options.
• Indirect beneficial ownership includes 1,025,063 Ordinary Shares held by a family trust, 3,953,100 Ordinary Shares held by Wang Investment LLC, and 50 Ordinary Shares held by his spouse, for which Mr. Wang disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While significant insider sales can be perceived negatively, they were conducted under a pre-planned Rule 10b5-1 plan, indicating a structured liquidity event rather than a reactive sell-off. This is balanced by the simultaneous grant of new equity compensation (RSUs and options), which aligns the insider's future interests with the company's performance.

Positives

• The grant of 98,696 Restricted Share Units (RSUs) at a $0 price and 185,796 Share Options at an exercise price of $20.26 aligns the director's interests with long-term company performance.
• The adoption of a Rule 10b5-1 trading plan demonstrates a pre-planned and transparent approach to insider stock sales, reducing concerns about opportunistic trading.

Negatives

• The sale of 41,760 American Depositary Shares (ADSs) by a director and 10% owner, totaling approximately $10.98 million, represents a significant reduction in direct beneficial ownership, which could be perceived negatively by investors.

Risks

• No specific new risks to the company's operations or financial health were disclosed in this Form 4 filing, as it primarily details insider trading activity.

Future Outlook

The document indicates future vesting schedules for the newly granted Restricted Share Units and Share Options, with vesting periods extending over four years from June 10, 2025, subject to continued service. No other forward-looking statements regarding the company's performance or strategic direction were provided.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
• The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Industry Context

This Form 4 filing is specific to insider trading activity at BeOne Medicines Ltd. and does not provide broader industry context or trends. It reflects individual compensation and liquidity management for a key executive within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans for insider sales is a standard practice among executives in publicly traded companies, including those in the biotechnology and pharmaceutical industries, to manage personal liquidity while adhering to insider trading regulations.
• The granting of Restricted Share Units (RSUs) and stock options as part of executive compensation packages is also a common practice across industries, including the life sciences, to incentivize long-term performance and align executive interests with shareholders.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 1,025,063 Ordinary Shares held by a family trust, for which the Reporting Person disclaims beneficial ownership.
• Indirect beneficial ownership of 3,953,100 Ordinary Shares held by Wang Investment LLC, where 99% of the LLC interest is owned by two grantor retained annuity trusts, for which the Reporting Person disclaims beneficial ownership.
• Indirect beneficial ownership of 50 Ordinary Shares held by the spouse of the Reporting Person.

Stakeholder Impact

• Shareholders may interpret the significant insider sales as a signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic selling.
• The grant of new equity compensation to a key director and scientific advisor reinforces alignment with shareholder interests for future performance.

Next Steps

• Vesting of 98,696 Ordinary Shares (RSUs) will occur annually, with 25% vesting on each anniversary of June 10, 2025.
• Vesting of 185,796 Share Options will occur over a four-year period, with 25% vesting on the first anniversary of June 10, 2025, and the remainder in 36 equal successive monthly installments.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Stock Options, Restricted Share Units, American Depositary Shares, Rule 10b5-1 Plan, Beneficial Ownership, Director Transactions